Abstract
Direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban have been endorsed by clinical practice guidelines for the outpatient treatment of venous thromboembolism (VTE). Concerns have been raised from registries about a high rate of abnormal uterine bleeding (AUB) associated with DOACs. To further explore the hypothesis that the frequency of AUB is different between women with venous thromboembolism treated with rivaroxaban versus apixaban, we conducted a secondary analysis of a multicenter implementation trial of patients discharged from the emergency department (ED) on VTE monotherapy that employed both of these anticoagulants.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
